Analysts predict that the new vaccine will have sales of $38 billion by 2021

China recently authorized an emergency trial to market the COVID-19 vaccine developed by Pfizer/BioNTech, and overseas analysts predict annual sales of the COVID-19 vaccine will reach $38 billion in 2021.
Pfizer/BioNTech, Moderna and AstraZeneta are pompishing on the top three.
the UK is the first country in the world to grant emergency access to the new mRNA vaccine BNT162b2.
BNT162b2 is expected to be licensed for emergency use in more countries around the world in the coming days and weeks, according to Pfizer/BioNTech, and the two companies are ready to supply vaccines.
/BioNTech plans to deliver about 800,000 doses in the UK next week, with a total of 40 million orders placed in the UK, the Guardian reported.
the first COVID-19 vaccine is expected to begin in the coming weeks, foreign media reported.
is important for companies in the head of COVID-19 vaccine development to capture market share in 2021.
analysts at Bernstein predict that the top five companies will have sales of about $38.5bn, with the first companies to list gaining more than half of the market share.
BNT162b2 vaccine, developed by Pfizer/BioNtech, is currently priced at $19.50 per dose and requires $39 per person for two injections.
Pfizer has disclosed that it expects to have more than 1.3 billion doses of capacity by the end of 2021 and has received hundreds of millions of metered orders, including 100 million dose orders ($1.95 billion) from the U.S. government and 400 million doses that may follow.
analysts say total sales of COVID-19 vaccines are declining year-on-year after a huge release in 2021.
Assume that vaccinators need to be more vaccinated every three years, the market share is expected to be $23.1 billion in 2022, to $12.6 billion by 2023, to $8.5 billion by 2024 and to about $6 billion by 2025.
note that the analyst's model currently considers only a few leading vaccine developers with an absolute advantage.
the supply of vaccines flows first to developed markets, emerging markets will be supplied as demand in developed markets declines, analysts wrote.
they expect that if the U.S. were to be immunized in June, other developed markets such as the U.S., Canada, Japan and Europe would reach mass immunization in August or September.
In terms of vaccine efficiency, Pfizer and Moderna have a higher efficiency, while AstraZeneta's two full doses are relatively low, and AstraZene half a year ago, Chief Executive Pascal Soriot said recently that AstraZenecom would conduct additional research to win FDA approval.
/BioNTech filed an emergency authorization application for the COVID-19 vaccine with the FDA on November 20, and the FDA plans to meet on December 10 to discuss whether to approve its emergency use authorization request.
Moderna also disclosed that the FDA will hold a consultation meeting on COVID-19 vaccine mRNA-1273 on December 17, and its CEO said it was likely that Moderna would be granted emergency use as soon as 24 to 72 hours after the December 17 meeting, and that 20 million doses of the vaccine could be released in the United States by the end of the year.
: The $38B Pie: Pfizer, Moderna COVID-19 vaccines set for lion's share of 2021 sales Medicine Rubik's Cube Source: Pharmaceutical Rubik's Cube Copyright Notice: All text, images and audio and video materials on this website that state "Source: Mets Medicine" or "Source: MedSci Original" are owned by Mets Medical and are not authorized to be reproduced by any media, website or individual, and are authorized to be reproduced with the words "Source: Mess Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here